Tekmira Pharmaceuticals Corporation Announces New Preclinical Data From Anti-Viral Programs

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VANCOUVER, British Columbia, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced positive preclinical data demonstrating the anti-viral efficacy of its TKM-Ebola and TKM-Marburg programs when treatment is delayed following infection.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC